1.83

1.61% -0.03

Chemomab Therapeutics Ltd Adr (CMMB)

Panoramica Notizia Cronologia dei prezzi Financials Forum Previsione

Precedente Chiudi:

$1.86

Aprire:

$1.92

Volume 24 ore:

23,252

Relative Volume:

0.27

Capitalizzazione di mercato:

$11.26M

Reddito:

Utile/perdita netta:

$-10.14M

Rapporto P/E:

-0.9846

EPS:

-1.8587

Flusso di cassa netto:

$-23.55M

1 W Prestazione:

-2.66%

1M Prestazione:

+21.19%

6M Prestazione:

-39.65%

1 anno Prestazione:

+31.65%

Intervallo 1D:

$1.80

$1.92

Intervallo di 1 settimana:

$1.80

$2.1499

Portata 52W:

$0.8288

$3.855

Chemomab Therapeutics Ltd Adr Stock (CMMB) Company Profile

Nome

Chemomab Therapeutics Ltd Adr

Settore

Healthcare (1116)

Industria

Biotechnology (621)

Telefono

972-77-331-0156

Indirizzo

KIRYAT ATIDIM, BUILDING 7, TEL AVIV

Dipendente

Cinguettio

Prossima data di guadagno

2026-03-16

Ultimi documenti SEC

CMMB's Discussions on Twitter

Compare CMMB vs VRTX, REGN, ARGX, ALNY, ONC

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
CMMB Chemomab Therapeutics Ltd Adr	1.83	11.26M	0	-10.14M	-23.55M	-1.8587
VRTX Vertex Pharmaceuticals Inc	469.34	119.23B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	745.77	78.84B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	700.45	43.35B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	313.41	41.57B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	284.05	31.51B	5.36B	287.73M	924.18M	2.5229

Chemomab Therapeutics Ltd Adr Stock (CMMB) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-05-13	Iniziato	Maxim Group	Buy
2024-05-06	Aggiornamento	Oppenheimer	Perform → Outperform
2023-12-19	Ripresa	ROTH MKM	Buy

Chemomab Therapeutics Ltd Adr Borsa (CMMB) Ultime notizie

Feb 23, 2026

Chemomab Therapeutics (CMMB) to Release Quarterly Earnings on Monday - Defense World

Feb 23, 2026

Dec 17, 2025

Pre Market Movers: DBVT, YCBD, KYTX Set The Pace - RTTNews

Dec 17, 2025

Dec 12, 2025

Chemomab Therapeutics (NASDAQ:CMMB) Shares Down 4.5% – Time to Sell? - Defense World

Dec 12, 2025

Dec 02, 2025

Chemomab’s nebokitug shows disease-modifying potential in PSC trial - Investing.com

Dec 02, 2025

Chemomab’s nebokitug shows disease-modifying potential in PSC trial By Investing.com - Investing.com UK

Dec 02, 2025

Nov 21, 2025

Chemomab Therapeutics (NASDAQ:CMMB) Cut to “Hold” at Zacks Research - Defense World

Nov 21, 2025

Nov 06, 2025

Chemomab reports positive 48-week data for PSC drug nebokitug - Investing.com

Nov 06, 2025

Oct 23, 2025

ALKS to Enter Sleep Disorder Market With $2.1B Avadel Acquisition - sharewise.com

Oct 23, 2025

Best Momentum Stocks to Buy for Oct. 23 - The Globe and Mail

Oct 23, 2025

New Strong Buy Stocks for Oct. 23: MQ, GES and More - Yahoo Finance

Oct 23, 2025

Oct 22, 2025

NVO's Rybelsus Gets FDA Nod to Reduce Heart Risk in Diabetes Patients - sharewise.com

Oct 22, 2025

SNY's Efdoralprin Alfa Meets Key Endpoints in Rare Disease Study - Yahoo Finance

Oct 22, 2025

Oct 21, 2025

Roche's Gazyva Secures FDA Nod for Label Expansion in Lupus Nephritis - sharewise.com

Oct 21, 2025

Oct 17, 2025

ESPR Aims to Diversify With Rare Liver Disease Candidate, Stock Up - The Globe and Mail

Oct 17, 2025

Oct 16, 2025

Viatris Acquires Aculys Pharma to Expand Neurology Portfolio in Japan - sharewise.com

Oct 16, 2025

Oct 15, 2025

RCKT Stock Up as FDA Accepts Resubmitted BLA for Gene Therapy - sharewise.com

Oct 15, 2025

Oct 14, 2025

TVRD Stock Plunges 84% After Phase II Fibrosis Study Misses Key Goals - Zacks Investment Research

Oct 14, 2025

Oct 13, 2025

Zoetis Gains CVMP Backing for Lenivia, Eyes EU Approval in Dog OA Pain - sharewise.com

Oct 13, 2025

TEVA Gets FDA Nod for Uzedy Label Expansion in Bipolar I Disorder - Yahoo Finance

Oct 13, 2025

Oct 11, 2025

Chemomab Therapeutics (NASDAQ:CMMB) Upgraded by Wall Street Zen to “Hold” Rating - Defense World

Oct 11, 2025

Oct 10, 2025

CDTX Stock Up on FDA's Breakthrough Therapy Tag for CD388 in Influenza - sharewise.com

Oct 10, 2025

OVID Stock Soars 39% in a Month Following Upbeat Epilepsy Study Data - sharewise.com

Oct 10, 2025

Oct 08, 2025

KALA Stock Crashes 88% in a Month Following Eye Disorder Study Failure - The Globe and Mail

Oct 08, 2025

AstraZeneca's Baxdrostat Meets Goal in Resistant Hypertension Study - Yahoo Finance

Oct 08, 2025

Oct 07, 2025

MRK Expands Tulisokibart Program in Three New Inflammatory Diseases - Nasdaq

Oct 07, 2025

Sep 01, 2025

Chemomab Therapeutics Ltd Share Price ADR Each Representing 80 Ord Shares SPON - Hargreaves Lansdown

Sep 01, 2025

Aug 27, 2025

Oppenheimer raises Chemomab stock price target to $25 on M&A potential - Investing.com

Aug 27, 2025

Jun 06, 2025

CADL Up as FDA Grants RMAT Status to CAN-2409 in Prostate Cancer - The Globe and Mail

May 29, 2025

May 28, 2025

TEVA Begins IND-Enabling Studies on Inflammatory Disease Candidate - Finviz

May 28, 2025

Oct 01, 2024

Chemomab Therapeutics to Present at October 2024 Investor Conferences By Investing.com - Investing.com

Oct 01, 2024

Jul 25, 2024

Chemomab secures $10 million in PIPE financing - Investing.com

Jul 25, 2024

Jun 27, 2024

Chemomab Therapeutics (CMMB) Upgraded to Buy: Here's What You Should Know - Yahoo Finance

Jun 27, 2024

May 26, 2024

Chemomab Therapeutics (CMMB) Stock Trends and Sentiment 2025 - MarketBeat

May 26, 2024

May 11, 2024

Chemomab Therapeutics (CMMB) Stock Forecast and Price Target 2026 - MarketBeat

May 11, 2024

Mar 27, 2024

Chemomab Therapeutics Ltd. Sponsored ADR Earnings and Revenue – NASDAQ:CMMB - TradingView — Track All Markets

Mar 27, 2024

Feb 14, 2024

symbol__ Stock Quote Price and Forecast - CNN

Feb 14, 2024

Nov 16, 2023

Chemomab (CMMB) Up on Fast Track Designation to CM-101 for PSC - Yahoo Finance

Nov 16, 2023

Nov 09, 2022